title: Frequency of minisatellite repeat number changes at the MS205 locus in human sperm before and after cancer chemotherapy.
abstract: To determine whether the measurement of repeat number mutations at a minisatellite locus could detect human germline mutations induced by chemotherapy, we performed a longitudinal study of the mutation frequencies in sperm from 10 patients treated for Hodgkin's disease. Polymerase chain reaction on small pools of DNA equivalent to 100 sperm and Southern blotting were used to screen at least 7900 sperm in each sample to quantify the mutation frequency at the minisatellite MS205 locus. Pretreatment and posttreatment semen samples were obtained at least 2 months after completion of therapy from 4 patients treated with a regimen (Novantrone, Oncovin, vinblastine and prednisone [NOVP]) that lacks alkylating agents and from three patients treated with regimens (Cytoxan, vinblastine, procarbazine and prednisone/Adriamycin, bleomycin, dacarbazine, lomustine, and prednisone [CVPP/ABDIC] or mechlorethamine, Oncovin, procarbazine and prednisone [MOPP]) containing alkylating agents. There were no effects of NOVP or CVPP/ABDIC on the mutation frequencies. In the 1 patient treated with MOPP, the treatment with the highest dose of gonadotoxic alkylating agents, there was a statistically significant increase in mutation frequency from 0.79% pretreatment to 1.14% posttreatment, indicating induction of mutations in stem spermatogonia. During-treatment semen samples obtained from 2 patients treated with ABVD, which does not contain gonadotoxic alkylating agents, and 1 with NOVP also did not show any increases above the baseline mutation frequencies, indicating no increase in the minisatellite mutation frequency in spermatocytes. Thus, measurement of repeat number changes at minisatellite MS205 appears to be able to detect induced germline mutations in human sperm. However, most chemotherapy regimens do not significantly increase this class of mutations.
authors.affiliation: Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: N
authors.initials: N
authors.lastname: Zheng
authors.forename: D G
authors.initials: DG
authors.lastname: Monckton
authors.forename: G
authors.initials: G
authors.lastname: Wilson
authors.forename: F
authors.initials: F
authors.lastname: Hagemeister
authors.forename: R
authors.initials: R
authors.lastname: Chakraborty
authors.forename: T H
authors.initials: TH
authors.lastname: Connor
authors.forename: M J
authors.initials: MJ
authors.lastname: Siciliano
authors.forename: M L
authors.initials: ML
authors.lastname: Meistrich
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001773:Blood Cells / Q000187:drug effects; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D018895:Microsatellite Repeats / Q000187:drug effects*; D009154:Mutation; D016133:Polymerase Chain Reaction / Q000379:methods; D012509:Sarcoma / Q000188:drug therapy; D013094:Spermatozoa / Q000187:drug effects* / Q000502:physiology*; D013583:Synovial Membrane; D013997:Time Factors